IASO207 injection for relapsed or resistant B-cell lymphoma
Part of Cancer clinical trials.
This early-stage trial tests IASO207, a new injection designed to treat B-cell lymphomas (blood cancers) that have come back or stopped responding to standard treatments. The drug targets a protein called CD19 found on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old
- Diagnosed with specific types of B-cell lymphoma (such as DLBCL, follicular lymphoma, or Richter transformation) that returned or didn't respond to prior standard chemotherapy and antibody therapy
- Cancer cells test positive for CD19 protein
- At least one measurable tumor lesion visible on imaging
- Adequate organ function (heart, lungs, liver, kidneys, blood counts) confirmed by recent lab tests
- No prior CD19-targeted treatments or certain other recent cancer therapies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
This trial tests a new drug, ISM8207, for people with advanced solid tumors or certain B-cell lymphomas that have not responded to standard treatments. It aims to see if the drug is safe and effective.
This trial tests an experimental drug called MTM-H-001 given as an injection. It's for people with B-cell lymphoma that has returned or not responded to standard treatments, and it aims to see if the drug can help control the cancer.
This trial tests a new treatment called IASO208 for people with certain types of B-cell lymphoma that have come back or not responded to standard treatments. It aims to see if the drug can help shrink tumors and control the cancer.
This trial tests a new treatment called IASO206 for people with multiple myeloma that has come back or not responded to previous treatments. The therapy targets a protein called BCMA on myeloma cells, which may help control the disease.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Hear when a new Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.